Loading…
Krsnaa Diagnostics (KRSNAA)₹493.60+1.70%Healthcare Service Provider
In the Jun 2026 quarter (consolidated), Krsnaa Diagnostics reported sales of ₹236 Cr, up 22.2% from Jun 2025, and net profit of ₹16.99 Cr, down 19.0% year on year. For the year to Mar 2026, sales were ₹772 Cr and net profit ₹101 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 155 | 158 | 166 | 170 | 186 | 175 | 186 | 193 | 206 | 181 | 193 | 236 |
| Expenses | 124 | 121 | 124 | 129 | 138 | 130 | 134 | 143 | 148 | 136 | 139 | 179 |
| Operating Profit | 32.11 | 37.12 | 44.15 | 43.11 | 49.19 | 45.16 | 53.15 | 51.15 | 59.16 | 46.15 | 55.18 | 58.23 |
| OPM % | 20.0% | 23.9% | 25.9% | 24.9% | 26.9% | 25.9% | 28.0% | 26.9% | 28.9% | 25.9% | 27.9% | 25.0% |
| Other Income | 3.99 | 3.99 | 3.99 | 6.98 | 4.99 | 8.98 | 3.99 | 3.99 | 3.99 | 3.99 | 31.91 | 6.98 |
| Interest | 2.99 | 3.99 | 6.98 | 4.99 | 5.99 | 5.98 | 6.99 | 5.98 | 7.98 | 7.98 | 11.97 | 14.96 |
| Depreciation | 19.03 | 21.01 | 18.03 | 21.03 | 22.02 | 23.04 | 22.02 | 22.03 | 24.01 | 23.01 | 23.02 | 28.02 |
| Profit before tax | 12.99 | 15.99 | 22.99 | 22.97 | 24.97 | 24.97 | 28.99 | 26.98 | 31.98 | 19.99 | 51.91 | 21.97 |
| Tax % | 22.0% | 19.0% | 17.0% | 23.0% | 22.9% | 24.0% | 28.0% | 24.9% | 24.0% | 22.9% | 19.0% | 26.0% |
| Net Profit | 9.99 | 12.99 | 18.99 | 17.99 | 19.97 | 18.99 | 20.99 | 20.98 | 23.96 | 14.98 | 41.94 | 16.99 |
| EPS (Rs) | 3.33 | 4.01 | 5.79 | 5.53 | 6.05 | 6.00 | 6.38 | 6.32 | 7.36 | 4.69 | 12.83 | 5.09 |
| Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 38.94 | 60.92 | 454 | 486 | 619 | 717 | 772 | 815 |
| Expenses | 30.13 | 42.13 | 325 | 366 | 477 | 529 | 563 | 600 |
| Operating Profit | 9.03 | 19.07 | 133 | 122 | 144 | 191 | 213 | 219 |
| OPM % | 22.9% | 31.0% | 28.9% | 25.0% | 22.9% | 27.0% | 26.9% | 26.8% |
| Other Income | 2.99 | 1.99 | 14.98 | 18.97 | 16.97 | 25.92 | 42.88 | 46.87 |
| Interest | 8.98 | 8.98 | 17.95 | 7.97 | 15.96 | 24.96 | 33.93 | 42.89 |
| Depreciation | 6.01 | 12.01 | 41.03 | 54.07 | 75.14 | 88.08 | 90.07 | 98.06 |
| Profit before tax | −2.99 | 0.00 | 86.89 | 79.85 | 69.97 | 103 | 130 | 126 |
| Tax % | 48.9% | 180.0% | 20.9% | 22.9% | 19.0% | 24.0% | 22.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.99 | 0.00 | — |
| Net Profit | −4.99 | 0.00 | 67.94 | 61.99 | 56.98 | 77.97 | 101 | 97.87 |
| EPS (Rs) | −9.50 | −0.13 | 21.74 | 19.74 | 17.57 | 23.97 | 31.20 | 29.97 |
| Dividend payout % | 0.0% | 0.0% | 10.9% | 13.9% | 13.9% | 11.0% | 6.0% | — |
| Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 4.98 | 4.98 | 16.00 | 16.02 | 16.01 | 16.01 | 15.97 |
| Reserves | 5.98 | 5.98 | 670 | 724 | 795 | 868 | 963 |
| Borrowings | 131 | 102 | 41.18 | 32.13 | 161 | 205 | 536 |
| Other Liabilities | 43.99 | 79.92 | 151 | 138 | 202 | 193 | 310 |
| Total Liabilities | 186 | 192 | 876 | 910 | 1,173 | 1,281 | 1,827 |
| Fixed Assets | 74.22 | 131 | 387 | 472 | 649 | 672 | 658 |
| CWIP | 20.07 | 6.02 | 28.08 | 25.08 | 10.04 | 3.01 | 209 |
| Investments | 1.01 | 1.01 | 0.00 | 0.00 | 0.00 | 32.08 | 57.14 |
| Other Assets | 91.08 | 55.05 | 461 | 413 | 514 | 574 | 902 |
| Inventories | 1.01 | 1.01 | 9.03 | 25.04 | 36.11 | 29.09 | 27.05 |
| Trade receivables | 7.97 | 13.95 | 57.82 | 72.73 | 175 | 277 | 295 |
| Cash & equivalents | 37.86 | 6.97 | 241 | 109 | 174 | 67.75 | 360 |
| Total Assets | 186 | 192 | 876 | 910 | 1,173 | 1,281 | 1,827 |
| Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | −22.95 | 63.89 | 128 | 75.90 | 23.94 | 86.90 | 143 |
| Cash from investing activity | −47.15 | −54.18 | −242 | −109 | −130 | −100 | −398 |
| Cash from financing activity | 105 | −41.08 | 176 | −33.06 | 84.15 | 14.04 | 280 |
| Net cash flow | 36.01 | −30.99 | 63.96 | −66.01 | −19.99 | 1.01 | 26.01 |
| Capex | 47.14 | 54.21 | 132 | 142 | 195 | 127 | 220 |
| Free cash flow | −69.17 | 10.02 | −3.01 | −58.10 | −169 | −24.04 | −72.12 |
| CFO / OP % | −254.1% | 343.9% | 103.0% | 73.0% | 29.9% | 55.9% | 80.9% |
| Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 79 | 84 | 46 | 55 | 104 | 141 | 140 |
| Inventory days | 22 | 25 | — | — | — | — | 55 |
| Days payable | 76 | 100 | — | — | — | — | 129 |
| Cash conversion cycle | 23 | 7 | 45 | 54 | 103 | 140 | 64 |
| Working capital days | −69 | −113 | −23 | 11 | −21 | 21 | 48 |
| ROCE % | — | 7.0% | — | 12.1% | 10.0% | 12.1% | 13.1% |
For the Jun 2026 quarter, Krsnaa Diagnostics reported sales of ₹236 Cr, up 22.2% year on year and net profit of ₹16.99 Cr, down 19.0% year on year. The operating margin was 25.0%.
Krsnaa Diagnostics' sales for the year to Mar 2026 were ₹772 Cr; over the last twelve months they were ₹815 Cr.
Net profit for the year to Mar 2026 was ₹101 Cr, and ₹97.87 Cr over the last twelve months. Earnings per share over the same trailing period were ₹29.97.
Krsnaa Diagnostics reported borrowings of ₹536 Cr at Mar 2026, against cash and equivalents of ₹360 Cr.
Cash from operations was ₹143 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹72.12 Cr.